During the past decade, Eye Associates of Pinellas conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Eye Associates of Pinellas" are "Diabetic Retinopathy" (1 trials), "Geographic Atrophy" (1 trials), "Geographic Atrophy Secondary to Age-related Macular Degeneration" (1 trials), "Macular Edema" (1 trials) and "Neovascular Age-Related Macular Degeneration" (1 trials). Many other conditions were trialed in "Eye Associates of Pinellas" in a lesser frequency.

Most popular intervention types in "Eye Associates of Pinellas" are "Drug" (5 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "APL-2" (1 trials), "Aflibercept" (1 trials), "Drug: GB-102" (1 trials), "Lucentis or Avastin" (1 trials) and "PEGCETACOPLAN (APL-2)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Eye Associates of Pinellas" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Eye Associates of Pinellas". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Eye Associates of Pinellas, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Eye Associates of Pinellas, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".